Edition:
United Kingdom

Repligen Corp (RGEN.OQ)

RGEN.OQ on NASDAQ Stock Exchange Global Select Market

35.57USD
12 Dec 2017
Change (% chg)

$0.22 (+0.62%)
Prev Close
$35.35
Open
$35.49
Day's High
$35.71
Day's Low
$35.26
Volume
85,895
Avg. Vol
137,661
52-wk High
$46.81
52-wk Low
$28.49

Chart for

About

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $1,667.74
Shares Outstanding(Mil.): 43.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Repligen reports Q3 adjusted non-GAAP earnings per share $0.15

* Q3 earnings per share view $0.11 -- Thomson Reuters I/B/E/S

09 Nov 2017

BRIEF-Repligen extends long term supply agreement with Purolite for Protein A ligands

* Repligen extends long term supply agreement with Purolite for Protein A ligands

07 Nov 2017

BRIEF-Roy Eddleman reports 11 pct passive stake in Repligen‍​

* Roy T. Eddleman reports 11.0 percent passive stake in Repligen Corp as of August 1, 2017 - sec filing‍​ Source text: (http://bit.ly/2vRsiEb) Further company coverage:

21 Aug 2017

BRIEF-Repligen prices public offering of shares of common stock

* Repligen Corporation prices public offering of shares of common stock

28 Jun 2017

BRIEF-REPLIGEN CORP ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

* REPLIGEN CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

26 Jun 2017

BRIEF-Repligen and Spectrum to join forces

* Repligen Corp - deal expected to be accretive to repligen earnings per share in fiscal 2018

23 Jun 2017

Competitors

Earnings vs. Estimates